OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
3
Results
Show all
Save search
Copy query
Show results for
Unknown
(3)
Publication Date
Release Date
2025
(1)
2017
(1)
2016
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naive Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
Not available
S-EPMC5455701
|
biostudies-literature
Cite
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Not available
S-EPMC4800035
|
biostudies-literature
Cite
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Not available
S-EPMC12303861
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
